Floatz logo

Monalizumab

Unresectable

MedImmune LLCmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Unresectable cohort.

Asset / SponsorPhaseRating
Durvalumab
MedImmune LLC
Phase 2B
IMMUNOGLOBULIN G1, ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN MONOCLONAL MEDI9447 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI9447 .LAMBDA.-CHAIN, DIMER
MedImmune LLC
Phase 2B
Songyou
Fudan University
Phase 2CCC
IMMUNOGLOBULIN G, ANTI-(HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER
NantBioScience, Inc.
Phase 2CCC
Rec-1245
Recursion Pharmaceuticals Inc.
Phase 1/2CC

View all 10 →

Same molecule, other indications

Monalizumab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
COVID-19Dormant
B
Indicative ·
57 / 100
View asset →
neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →